Trevi Therapeutics Inc. announced positive topline results from its Phase 2a RIVER trial of Haduvio, a treatment for patients with refractory chronic cough. The trial met its primary endpoint, demonstrating a statistically significant reduction in 24-hour cough frequency, with a 57% placebo-adjusted change from baseline. Additionally, 84% of patients treated with Haduvio were classified as responders compared to 29% in the placebo group, and a 67% reduction in cough frequency from baseline was observed. Relief was noted by Day 7. Following the announcement, Trevi Therapeutics' stock ($TRVI) surged by 38.6% in pre-market trading, reflecting investor confidence in the potential of Haduvio. In related biotech news, Protagonist Therapeutics Inc. ($PTGX) reported positive top-line results from its Phase 2b study of Icotrokinra, showing promise in transforming the treatment paradigm for patients with ulcerative colitis. The stock rose by 22.90% in pre-market trading. Johnson & Johnson ($JNJ), a partner in the development of Icotrokinra, also reported that the drug achieved complete skin clearance in 46% of patients at week 24 in a psoriasis treatment study, suggesting potential to redefine psoriasis treatment. Beam Therapeutics Inc. ($BEAM) announced the pricing of an underwritten offering, raising $500 million through the sale of 16,151,686 shares at $28.48 each. The funds will be used to advance its platform technology and support ongoing research and development activities, including clinical trials for BEAM-101 and BEAM-302. The stock experienced a positive reaction to the news, though specific percentage changes were not disclosed.